Individual patients with a shared ailment can respond very differently to the same drug. This highly variable clinical response to drugs is reflective of the current ‘one size fits all’ approach adopted in much of clinical care, and effectively represents an extremely large unmet medical need across the disease spectrum. AlphaBiomics is developing precision medicine solutions based on the gut microbiome of patients in order to deliver safer and more efficacious drug therapies.